Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Front Endocrinol (Lausanne) ; 13: 867647, 2022.
Article de Anglais | MEDLINE | ID: mdl-35712244

RÉSUMÉ

The current widespread use of sodium-glucose co-transporter 2 (SGLT2) inhibitors has triggered an increase in reported cases of euglycemic diabetic ketoacidosis (EDKA), often characterized by a protracted metabolic acidosis that is resistant to conventional DKA treatment. We report a case of empagliflozin-induced EDKA with severe metabolic acidosis intractable to aggressive fluid resuscitation and boluses of bicarbonate infusion. Following the introduction of high-calorie glucose infusion coupled with tight glycemic control, the recalcitrant acidosis was successfully corrected. This is the first case report that adopts the above approach, representing a paradigm shift in the management of SGLT2 inhibitor-induced EDKA.


Sujet(s)
Diabète , Acidocétose diabétique , Inhibiteurs du cotransporteur sodium-glucose de type 2 , Composés benzhydryliques , Acidocétose diabétique/induit chimiquement , Acidocétose diabétique/traitement médicamenteux , Glucose , Glucosides/usage thérapeutique , Régulation de la glycémie , Humains , Inhibiteurs du cotransporteur sodium-glucose de type 2/effets indésirables
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE